Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 341

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison

Christopher Strouse, Surbhi Sidana, Rafael Fonseca, Joaquin Martinez-Lopez, Yaël Cohen, Binod Dhakal, Murali Janakiram, Suzy Van Sanden, João Mendes, Joris Diels, Seina Lee, Sundar Jagannath

Blood (2025) 146 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2025-4046

Published: 2025

Journal Articles

Integrative omics analysis of TP53 in multiple myeloma patients

Cristina De Ramón Sánchez, Elizabeta A Rojas, Irena Misieweicz, Maria García-Alvarez, Myriam Cuadrado, Sara Cristobal, Ignacio J Cardona-Benavides, Isabel M Isidro, Maria Calasanz, Miguel Alcoceba, Ramon Garcia-Sanz, Laura Rosiñol Dachs, Joaquin Martinez-Lopez, Joan Batista Blade Creixenti, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, María-Victoria Mateos, Luis Antonio Corchete Sanchez, Norma Gutiérrez

Blood (2025) 146 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2025-2162

Published: 2025

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2025-2562

Published: 2025

Journal Articles

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2025-2215

Published: 2025

Journal Articles

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

Almudena Zaratiegui Vergara, Gonzalo Carreño, Francisca Ferrer Marin, Blanca Xicoy, María Teresa Gómez Casares, Fermin Sanchez-Guijo, M Concepción Ruiz Nuño, Santiago Osorio Prendes, Raquel De Paz, Ana Isabel Rosell Mas, Elvira Mora Casterá, María Alicia Senin, Juan Carlos Hernandez Boluda, Rosa Ayala Diaz, Valentín García Gutiérrez, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2025-3778

Published: 2025

Journal Articles

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Blood (2025) 146 (Supplement 1): 135.

https://doi.org/10.1182/blood-2025-135

Published: 2025

Journal Articles

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4588.

https://doi.org/10.1182/blood-2025-4588

Published: 2025

Journal Articles

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 451.

https://doi.org/10.1182/blood-2025-451

Published: 2025

Journal Articles

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Roberto Mancebo-Martin, Magdalena Corona De Lapuerta, Lara Rodriguez-Luque, Cristian Gutiérrez Padilla, David Bermejo-Peláez, Nuria Diez Navarro, David Brau-Queralt, Nieves Lopez Muñoz, Rafael Alonso Fernandez, Jose Maria Sanchez Pina, Miguel Luengo-Oroz, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 6349.

https://doi.org/10.1182/blood-2025-6349

Published: 2025

Journal Articles

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Maria Sanchez-Tabernero, Magdalena Corona, Cristian Gutiérrez Padilla, Jose Sanchez-Pina, Rafael Alonso, Inmaculada Rapado, Nieves Lopez-Muñoz, Gonzalo Carreño, Susana Cortijo, Maria Teresa Cedena Romero, Manuela Fernández, Rosa Ayala Diaz, Maria Calbacho, Joaquin Martinez-Lopez

Blood (2025) 146 (Supplement 1): 5781.

https://doi.org/10.1182/blood-2025-5781

Published: 2025

Journal Articles

Prevalence, incidence, and outcomes of multiple myeloma patients using electronic health records and natural language processing

María-Victoria Mateos, Roberto Trelles, Fernando Escalante Barrigón, Francisco de la Rubia, Natalia Marin Huarte, Angela Garcia Garcia-Porrero, Ana Cáceres Nuñez, Rafael Rios Tamayo, Antonia Sampol Mayol, Eugenio Giménez, Jose Angel Hernandez Rivas, Jaime Perez de Oteyza, Teresa De Soto Alvarez, SRG Savana Research Group, Joaquin Martinez Lopez

Blood (2025) 146 (Supplement 1): 4566.

https://doi.org/10.1182/blood-2025-4566

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

Blood (2025) 146 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2025-5322

Published: 2025

Journal Articles

AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq

Juan Manuel Rosa-Rosa, Jordi Ribera, Mireia Morgades, Isabel Granada, Rosa Ayala Diaz, Susana Barrera, Alberto Hernández-Sánchez, Josgrey Del Valle Navas Acosta, María Herrero García, Esperanza Such, Anna Torrent, Rosa Coll, Marta Cervera, Clara Maluquer Artigal, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera, Joaquin Martinez-Lopez, Ricardo Sanchez

Blood (2025) 146 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2025-4358

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Integrative omics analysis of TP53 in multiple myeloma patients

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis

Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification

Prevalence, incidence, and outcomes of multiple myeloma patients using electronic health records and natural language processing

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only